SAS restated its figures for the 2012/2013 fiscal year

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 11, 2014 at 3:15 AM

SAS restated its figures for the 2012/2013 fiscal year (November-October) due to the amended standard IAS 19 – Employee Benefits

The SAS Group has applied the amended standard for pension reporting, IAS 19 – Employee Benefits since November 1, 2013. As part of implementing the amended accounting standard, reported figures for the preceding fiscal year (2012/2013) were restated to enable comparison with the 2013/2014 fiscal year. The effects of the restatement of the SAS Group’s financial statements for 2012/2013 can be found at www.sasgroup.net, under Investor Relations/Reports and Presentations/Interim reports. IAS 19 Employee Benefits (Amended) means that it is no longer permitted to defer recognition of certain deviations in estimates (the “corridor” approach has now been eliminated) and all estimates are to be immediately recognized in other comprehensive income. Deviations can, for example, be attributable to changes in discount rates, changed life expectancy assumptions and differences between the actual return on plan assets and the discount rate. Furthermore, interest expense and expected return on plan assets are replaced with a “net interest,” which is calculated using the discount rate used to measure the net defined -benefit pension liability or pension assets. The SAS Group classifies this net interest expense as a payroll expense and recognizes the net interest expense in operating income. Effect of the 2012/2013 fiscal year (restated figures): All historic unrecognized actuarial gains and losses and plan amendments were recognized in shareholders’ equity, which meant a negative effect of about SEK 13.5 billion as of November 1, 2012. Recognition of actuarial gains and losses as well as plan amendments also meant that deferred tax liabilities related to pensions were dissolved when the temporary difference between the accounting and tax values disappeared. The effect of the reversal of deferred tax liabilities related to pensions amounted to approximately SEK 1.5 billion, which had a positive impact on the SAS Group’s shareholders’ equity. The remaining pension plans in Sweden (the Alecta plan and Euroben) reported a surplus at November 1, 2012. This surplus may benefit SAS in the form of future reductions in premiums and, accordingly, special payroll tax will be recognized for the surplus. This resulted in a net increase in pension funds of about SEK 1.2 billion, deferred tax liabilities of about SEK 0.2 billion and shareholders’ equity of about SEK 1 billion. Actuarial gains and losses and plan amendments that arose in the 2012/2013 fiscal year were recognized in other comprehensive income in an amount of about SEK 1.8 billion. Operating income increased by MSEK 144 during the fiscal year. Capital gains/losses pertaining to the sale of 80% of the shareholding in Widerøe AS were adjusted in an amount of about SEK 1.1 billion. In total, this means that net pension funds declined MSEK 9,079, deferred tax liabilities were reduced by MSEK 1,202 and shareholders’ equity was reduced by MSEK 7,877 as of October 31, 2013. In addition, reclassification was performed of MSEK 264 transferred from deferred tax liabilities to deferred taxes recoverable. The reclassification has no impact on cash flow aside from certain reclassifications between items in the tables. The amended standard IAS 19 is also described in the SAS Group’s Annual Report for the 2012/2013 fiscal year. For further information, please contact: SAS Press Hotline: Tel. +46 (0) 8 797 2944 SAS Group Investor Relations SAS discloses this information pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act and corresponding Danish and Norwegian legislation. The information was provided for publication on March 11, 2014 at 8:00 a.m. (CET).

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ELEGOO Slashes Prices up to 54% for 2026 Holiday Deals

ELEGOO's 2026 Holiday Strategy: Deep Discounts Welcome to the world of sharp deals and crafty creations as ELEGOO kicks off its Black Friday and Cyber Monday extravaganza. This time, they're slashing prices by up to 54% on their impressive lineup of 3D printers and captivating accessories. Yeah, it's that time of year when wallets might take a hit, but for a good reason....

Ebix and intentyx Tackle AI Security in Regulated Fields

Ebix Aims to Rein in AI Mischief When you throw AI agents into the mix of regulated businesses like insurers, banks, and healthcare outfits, you get a storm brewing. Now, Ebix and intentyx seem to be donning their capes, aiming to bring clarity with their new SMARE security platform. Fancy name notwithstanding, this isn't about mind games—it's about real, observable...

Tennessee Highlights Alarming COPD Rates This November

Tennessee Turns the Spotlight on COPD Here we are again, looking at Tennessee with its weary lung health woes. Governor Bill Lee's newest proclamation for November as COPD Awareness Month is shining a light on a crisis that's been disproportionately hitting the state harder than a sideswipe from a semi. Why the Proclamation Matters Let's cut through the fog—COPD,...

Military Medical Minds to Converge at MTEC Event in 2027

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Blokees Joins 'MIKU WITH YOU 2026' Concert in China

Blokees Partners with Iconic Virtual Star Hatsune Miku There's a new player cozying up in the world of virtual icons, and it's none other than Blokees. If you haven't heard, Blokees just dipped its toes into the buzzing waters of the Hatsune Miku fandom by becoming an official strategic partner at the 'MIKU WITH YOU 2026' concert in Shanghai. You could call this a step up...

Julie Boland's Strategic Move to Deere's Board

Deere & Company Expands Leadership with Boland Out of the blue, Deer & Company (NYSE: DE) decided to shake things up by adding Julie Boland, the former U.S. honcho at Ernst & Young LLP, to their board. Now, when Deere gets a leader with her pedigree, there’s more than a whiff of strategy at play. Let’s unpack why Deere's pulling the trigger on this boardroom shift....

Maya Mobile Wins Best Global Roaming Services 2026

Travelers Speak: Maya Tops Global Roaming It's not every day that you see the travel community collectively high-five a company, but that's precisely what happened with Maya Mobile. These folks just snagged the Best Global Roaming Services title at the TripZilla Excellence Awards 2026, and it's not just fluff—it's voted by travelers. This ain't your typical pat on the...

Camect and 3Si Partnership: Revolutionizing Public Safety

Smarter Surveillance with Camect and 3Si A fresh collaboration is stirring the security pot, straight from Silicon Valley's buzzing tech nest. Camect, the brainiacs behind AI-powered video smarts, are shaking hands with 3Si Security Systems. In plain talk, they're hooking up Camect's sharp-eyed video tech with 3Si's DirectToDispatch™ system. This ain’t some techie...

Target Hospitality Readies for Q3 2026 Earnings Reveal

The Thrill of Earnings Season Every trader worth their salt gets a tingle down the spine come earnings season. There's nothing quite like it—the build-up, the anticipation, the potential payouts. This time, we're zeroing in on Target Hospitality, bearing the ticker NASDAQ: TH. Come November 9, 2026, they're set to unveil what the past quarter had up its sleeve, and like...

Ascletis Showcases Bold Moves in Obesity Drug Arena

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...